|By PR Newswire||
|February 27, 2014 07:00 AM EST||
WILMINGTON, Mass., Feb. 27, 2014 /PRNewswire/ -- Implant Sciences Corporation (OTCQB:IMSC), a high technology supplier of systems and sensors for homeland security and defense markets, announced today that its QS-B220 desktop explosives trace detection system has successfully completed and passed testing requirements of the Qualification Testing and Evaluation (QT&E) portion of the Transportation Security Administration's (TSA) Explosive Trace Detection (ETD) qualification test at the Transportation Systems Integration Facility (TSIF).
TSA's state-of-the-art TSIF, located at Ronald Reagan Washington National Airport, is where new screening technologies are tested before they are deployed to airports around the country. The facility provides an operational airport environment where TSA evaluates the technology by its concepts of operation, measures of performance, and measures of effectiveness.
In July 2013, the QS-B220 successfully completed the first step of QT&E, called Independent Testing and Evaluation (IT&E). QS-B220 has since passed the second step of QT&E at the TSIF, thereby fulfilling another important step towards qualifying the QS-B220 by the Transportation Security Administration and for use in major airports all across the US.
"Evaluation of our QS-B220 was a very important achievement that demonstrates the benefits of our ETD technology in action. The QS-B220 provides superior detection capabilities, a non-radioactive source, and operational and cost efficiencies that can deliver benefits at airport security checkpoints each year. The combination of enhanced performance and operational capabilities of the QS-B220 truly define the new standard of trace detection," stated Glenn D. Bolduc, Implant Sciences' President and CEO.
"Successfully completing QT&E brings us another step closer to completing TSA's Qualified Product List process, and we are confident that the QS-B220 will meet the remaining stringent testing requirements," added Dr. Darryl Jones, Vice President of Sales and Marketing at Implant Sciences.
About the QS-B220 Desktop Explosives Trace Detector
The QS-B220 uses Ion Mobility Spectrometry (IMS) to rapidly detect and identify trace amounts of a wide variety of military, commercial, and homemade explosives. With significantly lower maintenance requirements than competing systems, the QS-B220 can be deployed for a much lower total cost of ownership than other approved products. Featuring a radioactive material-free design, push-button maintenance and diagnostics, and a patented inCal™ internal automatic calibration system, the QS-B220 brings new levels of performance and convenience to desktop trace detection users with unsurpassed ease of use.
About Implant Sciences
Implant Sciences is the leader in next generation Explosives Trace Detection (ETD) technology. As of January 2013, the Company is only the third ETD manufacturer, and the first American-owned company, to currently have product approval from the US Transportation Security Administration. Implant Sciences has developed proprietary technologies used in its commercial explosives and drugs trace detection systems, which ship to a growing number of locations domestically and internationally. Implant Sciences' QS-H150 portable explosives trace detector has received Qualified Anti-Terrorism Technology Designation and, in addition to receiving TSA qualification for air cargo screening, the Company's QS-B220 has also received STAC certification, a Developmental Testing & Evaluation (DT&E) Designation by the U.S. Department of Homeland Security under the Support Anti-terrorism by Fostering Effective Technology Act of 2002 (the SAFETY Act), and the GSN 2013 Homeland Security Award for "Best Explosives Detection Solution". For further details on the Company and its products, please visit the Company's website at www.implantsciences.com.
Safe Harbor Statement
This press release may contain certain "forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements are based on management's current expectations and are subject to risks and uncertainties that could cause the Company's actual results to differ materially from the forward-looking statements. Such risks and uncertainties include, but are not limited to, the risks that we will be required to repay all of our indebtedness to our secured lender, DMRJ Group, by September 30, 2014; if we are unable to satisfy our obligations to DMRJ and to raise additional capital to fund operations, DMRJ may seize our assets and our business may fail; we continue to incur substantial operating losses and may never be profitable; our independent registered public accounting firm has expressed substantial doubt as to our ability to continue as a going concern; our explosives detection products and technologies (including any new products we may develop) may not be accepted by the Transportation Security Administration or by other U.S. or foreign government and law enforcement agencies or commercial consumers of security products; economic, political and other risks associated with international sales and operations could adversely affect our sales; liability claims related to our products or our handling of hazardous materials could damage our reputation and have a material adverse effect on our financial results; our business is subject to intense competition; our markets are subject to rapid technology change and our success will depend on our ability to develop and introduce new products; we may not be able to retain our management and key employees or identify, hire and retain additional personnel as needed; we may not be able to enforce our patent and other intellectual property rights or operate without infringing on the proprietary rights of others; and other risks and uncertainties described in our filings with the Securities and Exchange Commission, including our most recent Forms 10-K, 10-Q and 8-K. Such statements are based on management's current expectations and assumptions which could differ materially from the forward-looking statements.
Implant Sciences Corporation
Glenn Bolduc, CEO
SOURCE Implant Sciences Corporation
Kubernetes, Docker and containers are changing the world, and how companies are deploying their software and running their infrastructure. With the shift in how applications are built and deployed, new challenges must be solved. In his session at @DevOpsSummit at19th Cloud Expo, Sebastian Scheele, co-founder of Loodse, will discuss the implications of containerized applications/infrastructures and their impact on the enterprise. In a real world example based on Kubernetes, he will show how to ...
Aug. 26, 2016 09:15 PM EDT Reads: 1,420
Aug. 26, 2016 07:15 PM EDT Reads: 378
Aug. 26, 2016 07:00 PM EDT Reads: 640
Aug. 26, 2016 07:00 PM EDT Reads: 674
Aug. 26, 2016 06:00 PM EDT Reads: 1,914
Aug. 26, 2016 05:00 PM EDT Reads: 663
Aug. 26, 2016 04:45 PM EDT Reads: 1,525
Aug. 26, 2016 04:30 PM EDT Reads: 2,297
Aug. 26, 2016 04:00 PM EDT Reads: 3,927
Aug. 26, 2016 03:45 PM EDT Reads: 551
Aug. 26, 2016 03:15 PM EDT Reads: 410
Aug. 26, 2016 01:30 PM EDT Reads: 3,410
Aug. 26, 2016 01:00 PM EDT Reads: 1,974
Aug. 26, 2016 12:30 PM EDT Reads: 634
Aug. 26, 2016 11:45 AM EDT Reads: 669